BIOMAT Database Logo BIOMAT Database Logo

Design and synthesis of potent and highly selective thrombin inhibitors. 1994

K Hilpert, and J Ackermann, and D W Banner, and A Gast, and K Gubernator, and P Hadváry, and L Labler, and K Müller, and G Schmid, and T B Tschopp
Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Thrombin, a serine protease, plays a central role in the initiation and propagation of thrombotic events. An extensive search for new thrombin inhibitors was performed, using an unconventional approach. Screening of small basic molecules for binding in the recognition pocket of thrombin led to the discovery of (aminoiminomethyl)piperidine (amidinopiperidine) as a weak, but intrinsically selective, thrombin inhibitor. Elaboration of this molecule provided compounds which inhibit thrombin with Ki's in the range of 20-50 nM and with selectivities of 1000-4000 against trypsin. These inhibitor compounds show a new and unexpected binding mode to thrombin. Modification of the central building block and then of one of the hydrophobic substituents led to the discovery of a new family of thrombin inhibitors which has reverted to the former binding mode to thrombin. This last class of compounds shows inhibitory activities in the picomolar range, low toxicity, and a short plasma half life which favors its use for an intravenous application. From this series of thrombin inhibitors, 19f(Ro 46-6240) was selected for clinical development as an antithrombotic agent for intravenous administration.

UI MeSH Term Description Entries
D010880 Piperidines A family of hexahydropyridines.
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000596 Amino Acids Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. Amino Acid,Acid, Amino,Acids, Amino
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000991 Antithrombins Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. Antithrombin,Direct Antithrombin,Direct Antithrombins,Direct Thrombin Inhibitor,Direct Thrombin Inhibitors,Antithrombin, Direct,Antithrombins, Direct,Inhibitor, Direct Thrombin,Thrombin Inhibitor, Direct,Thrombin Inhibitors, Direct
D001224 Aspartic Acid One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter. (+-)-Aspartic Acid,(R,S)-Aspartic Acid,Ammonium Aspartate,Aspartate,Aspartate Magnesium Hydrochloride,Aspartic Acid, Ammonium Salt,Aspartic Acid, Calcium Salt,Aspartic Acid, Dipotassium Salt,Aspartic Acid, Disodium Salt,Aspartic Acid, Hydrobromide,Aspartic Acid, Hydrochloride,Aspartic Acid, Magnesium (1:1) Salt, Hydrochloride, Trihydrate,Aspartic Acid, Magnesium (2:1) Salt,Aspartic Acid, Magnesium-Potassium (2:1:2) Salt,Aspartic Acid, Monopotassium Salt,Aspartic Acid, Monosodium Salt,Aspartic Acid, Potassium Salt,Aspartic Acid, Sodium Salt,Calcium Aspartate,Dipotassium Aspartate,Disodium Aspartate,L-Aspartate,L-Aspartic Acid,Magnesiocard,Magnesium Aspartate,Mg-5-Longoral,Monopotassium Aspartate,Monosodium Aspartate,Potassium Aspartate,Sodium Aspartate,Aspartate, Ammonium,Aspartate, Calcium,Aspartate, Dipotassium,Aspartate, Disodium,Aspartate, Magnesium,Aspartate, Monopotassium,Aspartate, Monosodium,Aspartate, Potassium,Aspartate, Sodium,L Aspartate,L Aspartic Acid
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014361 Trypsin Inhibitors Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds. Trypsin Inhibitor,Inhibitor, Trypsin,Inhibitors, Trypsin
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

K Hilpert, and J Ackermann, and D W Banner, and A Gast, and K Gubernator, and P Hadváry, and L Labler, and K Müller, and G Schmid, and T B Tschopp
Design and synthesis of potent and selective macrocyclic thrombin inhibitors.
August 2003, Bioorganic & medicinal chemistry letters,
K Hilpert, and J Ackermann, and D W Banner, and A Gast, and K Gubernator, and P Hadváry, and L Labler, and K Müller, and G Schmid, and T B Tschopp
Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors.
April 1999, Bioorganic & medicinal chemistry letters,
K Hilpert, and J Ackermann, and D W Banner, and A Gast, and K Gubernator, and P Hadváry, and L Labler, and K Müller, and G Schmid, and T B Tschopp
Novel bicyclic lactam inhibitors of thrombin: highly potent and selective inhibitors.
April 2002, Bioorganic & medicinal chemistry letters,
K Hilpert, and J Ackermann, and D W Banner, and A Gast, and K Gubernator, and P Hadváry, and L Labler, and K Müller, and G Schmid, and T B Tschopp
Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors.
May 2018, Molecular diversity,
K Hilpert, and J Ackermann, and D W Banner, and A Gast, and K Gubernator, and P Hadváry, and L Labler, and K Müller, and G Schmid, and T B Tschopp
Design, synthesis, and pharmacological evaluation of highly potent and selective dipeptidyl peptidase-4 inhibitors.
June 2015, Archiv der Pharmazie,
K Hilpert, and J Ackermann, and D W Banner, and A Gast, and K Gubernator, and P Hadváry, and L Labler, and K Müller, and G Schmid, and T B Tschopp
Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors.
February 2014, ACS medicinal chemistry letters,
K Hilpert, and J Ackermann, and D W Banner, and A Gast, and K Gubernator, and P Hadváry, and L Labler, and K Müller, and G Schmid, and T B Tschopp
Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors.
May 2023, ACS medicinal chemistry letters,
K Hilpert, and J Ackermann, and D W Banner, and A Gast, and K Gubernator, and P Hadváry, and L Labler, and K Müller, and G Schmid, and T B Tschopp
Design and synthesis of potent, selective inhibitors of matriptase.
July 2012, ACS medicinal chemistry letters,
K Hilpert, and J Ackermann, and D W Banner, and A Gast, and K Gubernator, and P Hadváry, and L Labler, and K Müller, and G Schmid, and T B Tschopp
Design and Synthesis of Highly Potent and Specific ABHD6 Inhibitors.
November 2023, ChemMedChem,
K Hilpert, and J Ackermann, and D W Banner, and A Gast, and K Gubernator, and P Hadváry, and L Labler, and K Müller, and G Schmid, and T B Tschopp
Highly selective tripeptide thrombin inhibitors.
February 1993, Journal of medicinal chemistry,
Copied contents to your clipboard!